Mendus AB (publ)

Mendus AB (publ) is a biopharmaceutical company headquartered in Stockholm, Sweden, with additional offices in the Netherlands, specializing in the development of immunotherapies to combat tumor recurrence and enhance long-term survival for cancer patients. The company leverages dendritic cell biology to create off-the-shelf, cell-based products that activate the patient’s immune system against cancer and infectious diseases, prioritizing clinical efficacy alongside a favorable safety profile. Key programs include vididencel (formerly DCP-001), derived from the proprietary DCOne cell line and advancing in Phase II trials like ADVANCE-II and CADENCE for acute myeloid leukemia (AML), as well as Phase I ALISON for ovarian cancer; and ilixadencel, targeting established tumors through intratumoral immune priming in Phase 1/2 trials for soft tissue sarcomas. An NK cell program is also in preclinical development. Formerly Immunicum AB, Mendus rebranded in June 2022 following a 2020 merger and went public in 2013, positioning itself at the forefront of immunotherapy innovation in oncology. Led by CEO Erik Manting and supported by seasoned executives, a robust board, and a world-class Scientific Advisory Board, Mendus drives progress in cancer treatment through strategic alliances and ongoing clinical advancements.